Neurocrine Biosciences, Inc.
NBIX
Peringkat dalam Saham
#1578
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Harga Saham
$135.96
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$13.82B
Perubahan (1 hari)
-0.72%
Perubahan (1 tahun)
-2.95%
Negara
US
Perdagangan Neurocrine Biosciences, Inc. (NBIX)
Kategori
Healthcare
Margin Operasi untuk Neurocrine Biosciences, Inc. (NBIX)
Margin Operasi per October 2026 TTM: 23.38%
Menurut laporan keuangan dan harga saham terbaru dari Neurocrine Biosciences, Inc., margin operasi saat ini (TTM) adalah 23.38%. Pada akhir 2023, margin operasi perusahaan adalah 13.30%.
Riwayat margin operasi untuk Neurocrine Biosciences, Inc. dari 2000 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 23.38% | -3.47% |
| 2024 | 24.22% | 82.11% |
| 2023 | 13.30% | -20.50% |
| 2022 | 16.73% | 85.07% |
| 2021 | 9.04% | -41.98% |
| 2020 | 15.58% | 69.90% |
| 2019 | 9.17% | 12.38% |
| 2018 | 8.16% | -110.04% |
| 2017 | -81.27% | -91.73% |
| 2016 | -982.48% | 106.18% |
| 2015 | -476.51% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -1,701.88% | -62,669.12% |
| 2012 | 2.72% | -93.79% |
| 2011 | 43.82% | -206.98% |
| 2010 | -40.96% | -97.75% |
| 2009 | -1,817.47% | -17.24% |
| 2008 | -2,196.18% | -87.33% |
| 2007 | -17,340.03% | 5,903.75% |
| 2006 | -288.82% | 1,326.98% |
| 2005 | -20.24% | -67.06% |
| 2004 | -61.44% | 45.35% |
| 2003 | -42.27% | -92.64% |
| 2002 | -574.20% | 439.66% |
| 2001 | -106.40% | -56.40% |
| 2000 | -244.04% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.35% |
US
|
|
| -149.01% | -106.37% |
US
|
|
| 25.57% | -98.91% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.77% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.